Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors - Related Videos
10:55
Study of the DNA Damage Checkpoint using Xenopus Egg Extracts
0 Views •
Cited by 35 •
2012
Xenopus egg extract is a useful model system to investigate the DNA damage checkpoint. This protocol is for the preparation of Xenopus egg extracts and DNA damage checkpoint inducing reagents. These techniques are adaptable to a variety of DNA damaging approaches in the study of the DNA damage checkpoint signaling.
02:19
The Spindle Assembly Checkpoint
0 Views •
2023
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed. Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
02:19
The Spindle Assembly Checkpoint
0 Views •
2021
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed. Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
0 Views •
Cited by 6 •
2017
Toll-like receptor (TLR) signaling plays an important role in the pathophysiology of many human inflammatory diseases, and regulating TLR responses by bioactive nanoparticles is anticipated to be beneficial in many inflammatory conditions. THP-1 cell-based reporter cells provide a versatile and robust screening platform for identifying novel inhibitors of TLR signaling.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
FAQs
The key distinction lies in which inhibitory interaction is interrupted. CTLA-4 is one checkpoint target, whereas PD-1/PD-L1 blockade prevents signaling through a receptor-ligand pathway. Both interventions remove restraints on T cells, but treating them as interchangeable would obscure how different checkpoint signals contribute to immune regulation and antitumor responses.
Once inhibitory signaling is blocked, T cells can regain several coordinated functions rather than merely becoming present in a tumor. The overview identifies renewed activation, proliferation, and cytotoxic activity as linked outcomes. This matters biologically because an effective response requires both expansion of responsive cells and their ability to attack abnormal cells.
Response is not uniform across patients, which makes checkpoint biology more complex than a simple on-or-off treatment model. At the same time, excessive immune activation can produce immune-related adverse events. These two outcomes motivate research that explains why antitumor immunity varies and how it can be strengthened without losing control of immune regulation.
Durable responses in several cancers show that checkpoint blockade can produce effects that persist beyond an immediate change in immune activity. This outcome has helped transform immunotherapy research, shifting attention toward how immune regulation can be manipulated in cancer biology and how lasting antitumor control might be achieved.
Checkpoint signaling research supports biomarker development, which addresses the problem of variable patient responses. In this context, biomarkers are investigated to connect biological features with treatment outcomes, although the overview does not specify a single marker or testing procedure. Their broader value is guiding more informed study of response differences.
Combination therapies extend the research question beyond blocking one inhibitory signal at a time. Investigators can use checkpoint biology to explore how multiple treatment strategies might improve antitumor immunity, while safer regulatory approaches aim to limit immune-related adverse events. Together, these goals balance stronger tumor responses with tighter control of immune activation.